To assess the potential value of cytokeratins (CK) 8,18,19 as tumor markers
for thyroid diseases, a study was performed comparing serum CK 8, 18,19 le
vels in patients affected from thyroid carcinoma, adenoma, other benign thy
roid diseases and healthy volunteers as controls.
One hundred cases (65 patients and 35 controls) were examined. Thirty patie
nts had thyroid carcinoma (18 papillary - PTC, 8 follicular - FTC, 4 medull
ary - MTC), 19 non-toxic goiter, 10 thyroid adenoma, 6 chronic thyroiditis
and 35 healthy volunteers as controls. These controls were matched by age a
nd sex. The mean value of CK in benign thyroid diseases (36.1 U/L) was sign
ificantly higher (p <0.02) than that in healthy controls (29.6 U/L). The me
an value of CK in carcinomas (68.1 U/L) was significantly higher than that
in healthy controls (p <0.01) and benign thyroid diseases patients (p <0.05
). The positive rate of CK in thyroid carcinomas was 28.1%, while in benign
thyroid diseases was 17.8%. The CK sensitivity for thyroid carcinomas was
28.1%, with a specificity of 80% and accuracy of 70.4%. In PTC patients the
mean CK value was not significantly higher than in the benign diseases' gr
oup and in healthy subjects. No evident correlation between CK levels and t
umor mass was found. In FTC patients the mean value was significantly highe
r than in the benign diseases' group and in healthy subjects. Large tumors
showed the highest levels, while small tumor values were similar to the con
trol ones. In MTC patients the mean value was significantly higher than in
the benign diseases' group and in healthy subjects, with the highest peaks
in large tumors and metastatic tumors. The detection of increased values in
thyroid carcinomas with high metastatic potential (FTC and MTC) seems to c
onfirm the role of these antigens in predicting the malignancy's degree of
the neoplasm. These findings, if confirmed in larger series, could play an
important role in assessing the CK 8,18,19 serum level as a real prognostic
factor. Further repeated serum determinations after total thyroidectomy mi
ght indicate the role of CK 8,18,19 as serum markers predicting the risk of
metastases.